Dr. Jesse M. Cedarbaum is a neurologist whose career has focused on developing novel and improved therapeutic agents for neurodegenerative and neuropsychiatric disorders. Dr. Cedarbaum has a unique background of more than 30 years of drug development and clinical trials experience in academia, biotechnology and large and small pharmaceutical companies. Most recently, he led a team at Biogen that advanced three new compounds for potential treatment of Parkinson’s disease (PD) into the clinic, efforts that included development of novel biomarkers and digital health technologies. Currently, Dr. Cedarbaum serves as a consultant to the biotechnology and pharmaceutical industries and nonprofit disease advocacy groups and is an adjunct professor of neurology and psychiatry at Yale Medical School. At Yale, he has maintained an active research program in developing therapeutics for PD and other neurodegenerative diseases, as well as improving outcome measures for neurodegenerative disease clinical trials.